Results

Total Results: 406 records

Showing results for "company".

1. Appendix A2: FDA status of medical devices for glaucoma screening (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/glaucoma_screening-apendices-11-5-10.pdf
   December 23, 2009 - STREAK RETINOSCOPE RX-1 SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … SPOT RETINOSCOPE RX-3SP SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … STREAK RETINOSCOPE RX-3 SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … STREAK RETINOSCOPE RX-RP SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … STREAK RETINOSCOPE RX-RC SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD.

2. Appendix A2: FDA status of medical devices for glaucoma screening (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-screening-apendices-11-5-10.pdf
   December 23, 2009 - STREAK RETINOSCOPE RX-1 SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … SPOT RETINOSCOPE RX-3SP SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … STREAK RETINOSCOPE RX-3 SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … STREAK RETINOSCOPE RX-RP SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD. … STREAK RETINOSCOPE RX-RC SE 3/28/1995 NEITZ INSTRUMENTS COMPANY LTD.

3. Disposition of Comments Technical Brief 41: Evaluation of Mental Health Mobile Applications (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/mental-health-mobile-apps-disposition-of-comments.pdf
   May 20, 2022 - A technology company offering healthcare data and advice based on healthcare data and PHI it has obtained … the safety for phi privacy and safety away from hacking, there is nothing that evaluates the tech company … A complete analyses of the financial gains of the company is beyond the scope of this framework. … If they are selling the data or giving the other data to another company, this is no different than … Yet the technology company for most of these apps are not holding any liability and forces in the BAA

4. #14 SUBSTANCE ABUSE (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/substanceabuse_hi_impact.pdf
   January 01, 2012 - The company completed a meeting with U.S. … and Drug Administration (FDA) in October 2011 about preparing its new drug application and the company … The company plans to complete its submission by mid- 2012. … The company further asserted that additional data analyses confirmed the implant’s noninferiority to … The company stated plans to complete its submission by mid-2012.

5. Glaucoma-Treatment-Appendices-11-5-10-2 (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-treatment-appendices-11-5-10-2.pdf
   October 27, 2009 - equivalent; Premarket notification, 501(k) Page 1 of 13 Laser, ophthalmic Product code: HQF COMPANY … GLIDE UNTRAOCULAR LENS GUIDES SE 9/24/1985 Photocoagulator and Accessories Product code: HQB COMPANY … LASER IRAS SE 11/1/1985 Ultrasound, Cyclodestructive Product code: LZR COMPANY PRODUCT FDA STATUS … 501(k) Page 9 of 13 Electrosurgical cutting & coagulation & Accessories Product code: GEI COMPANY … BAERVELDT GLAUCOMA IMPLANT SE 2/11/1991 Endoilluminator Product code: MPA COMPANY PRODUCT FDA

6. Diabetes Mellitus (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_2012-12-10.pdf
   January 01, 2012 - This may be, in part, because this is the only product of the company developing it, and funding to … In November 2012, the company reported that the drug was successfully delivered continuously and … Available: http://www.fundinguniverse.com/company- histories/ALZA-Corporation-Company- History.html … http://www.fundinguniverse.com/company-histories/ALZA-Corporation-Company-History.html http://www.fundinguniverse.com … /company-histories/ALZA-Corporation-Company-History.html http://www.fundinguniverse.com/company-histories

7. Diabetes Mellitus (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_june_2012.pdf
   January 01, 2012 - Indianapolis (IN): Eli Lilly and Company; 2011 Jul 28 [accessed 2011 Aug 18]. [3 p]. … Indianapolis (IN): Eli Lilly and Company; 2011 Nov 8 [accessed 2011 Nov 11]. [3 p]. … Available: http://www.fundinguniverse.com/company- histories/ALZA-Corporation-Company- History.html … /ALZA-Corporation-Company-History.html http://www.fundinguniverse.com/company-histories/ALZA-Corporation-Company-History.html … http://www.fundinguniverse.com/company-histories/ALZA-Corporation-Company-History.html Executive Summary

8. Diabetes Mellitus (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/diabetes_hi_impact.pdf
   March 01, 2012 - Indianapolis (IN): Eli Lilly and Company; 2011 Jul 28 [accessed 2011 Aug 18]. [3 p]. … Indianapolis (IN): Eli Lilly and Company; 2011 Nov 8 [accessed 2011 Nov 11]. [3 p]. … Available: http://www.fundinguniverse.com/company- histories/ALZA-Corporation-Company- History.html … /ALZA-Corporation-Company-History.html http://www.fundinguniverse.com/company-histories/ALZA-Corporation-Company-History.html … http://www.fundinguniverse.com/company-histories/ALZA-Corporation-Company-History.html http://www.seagen.com

9. PEPTIC ULCER #11 (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/11_pepticulcer_potential_high_impact_june_2012.pdf
   January 01, 2012 - titration to a 1,000 ova per dose if no response is seen after 8 weeks (four treatments). 3 The company … The company requires a letter from a physician and a statutory declaration from the importer stating … that the worms are for personal use and constitute 3 months or fewer of treatment. 4 The company … Needham & Company reiterates a 'buy' on NPS Pharmaceuticals (NPSP); Gattex PDUFA date announced, … Available: http://www.streetinsider.com/Analyst+Comment s/Needham+%26+Company+Reiterates+a+Buy +on

10. #14 SUBSTANCE ABUSE (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1306.pdf
    June 01, 2013 - The company submitted a new drug application to the U.S. … In March 2013, an FDA advisory panel voted to recommend approval; however, on April 30, 2013, the company … The company has stated that it believes it has met the evidence requirements for approval and is formulating

11. #14 SUBSTANCE ABUSE (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/14_substanceabuse_potential_high_impact_june_2012.pdf
    January 01, 2012 - The company completed a meeting with the U.S. … The company planned to complete its submission by mid-2012. … The company further asserted that additional data analyses confirmed the implant’s noninferiority to … Available: http://www.voxiva.com/company/news/Voxiva_la unches_Text2Quit.html. 3. … https://integrity.prous.com/ http://www.voxiva.com/company/news/Voxiva_launches_Text2Quit.html http:/

12. hemangioma-protocol-141223 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/infantile-hemangioma_research-protocol.pdf
    December 23, 2014 - 212) 733-2323 235 East 42nd Street New York, NY 10017 Pharmacologic Agents – Immunomodulators Company … 3M Health Care Limited Loughborough LE11 1EP England Manufactured for Medicis, The Dermatology Company … Weston, FL 33326 Tel: (800) 706-5575 Pharmacologic Agents – Antineoplastics Company or Researcher … Road Andover, MA 01810 Tel: (978) 749-1000 Fax: (978) 749-1599 Pharmacologic Agents – Other Company … Pharma USA, LLC 272 Deerpath Rd. #304 Lake Forest, IL 60045 Tel: (847) 739-3246 Devices- Lasers Company

13. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1412.pdf
    December 01, 2014 - The company announced that it submitted a premarket approval application to FDA in July 2014; no date … The company submitted a premarket approval application to FDA; in June 2014, the Gastroenterology and … In September 2014, the company announced that its CE mark had been expanded to include the management … New York (NY): The New York Times Company; 2012 Apr 10 [accessed 2013 Feb 01]. [3 p]. … New York (NY): The New York Times Company; 2012 Jul 17 [accessed 2013 Feb 01]. [3 p].

14. Diabetes Mellitus (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1512.pdf
    December 01, 2015 - According to the company, the 460-patient FREEDOM-1 trial met all key endpoints. … The company also reported that 60 patients in FREEDOM-1 HBL had a 3.4% mean reduction in HbA1c, with … According to the company, ITCA ES-5 650 reduced HbA1c levels by 1.5% compared with 0.8% for … Further, the company stated that patients who received ITCA 650 demonstrated significantly greater … The company announced that at 52 weeks, “ITCA 650 results were superior vs.

15. Diabetes Mellitus (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1412.pdf
    January 01, 2015 - According to the company, the U.S. … The company reported in October 2014 that two phase III trials (FREEDOM 1 and FREEDOM 1 high baseline … According to the company, “the new Enlite Serter provides a simpler sensor insertion process with a … A company press release included results from the completed FREEDOM-1 trial.62 The company reported … Intarcia CEO to present company progress, interim phase 3 data, and key milestones at J.P.

16. PATIENTSLIKEME (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/clifford.pdf
    May 29, 2025 - Although we are a for-profit company, we consider ourselves a not-just- for-profit company. … We're a for-profit company with a social mission.

17. #14 SUBSTANCE ABUSE (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/14_substance_abuse_potential_high_impact_2012-12-11.pdf
    January 01, 2012 - The ES-4 company filed a new drug application with the U.S. … opioid-negative urine screens over the 24-week treatment period. 20 In an August 2011 press release, the company … The company further asserted that additional data analyses confirmed the implant’s noninferiority to … Available: http://www.voxiva.com/company/news/Voxiva_la unches_Text2Quit.html. 3. … http://www.voxiva.com/company/news/Voxiva_launches_Text2Quit.html http://www.voxiva.com/company/news/

18. Infectious Disease Including HIV/AIDS #09 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1506.pdf
    December 01, 2015 - Princeton (NJ): Bristol-Myers Squibb Company; 2014 Apr 7 [accessed 2014 May 15]. [3 p]. … New York (NY): Bristol-Myers Squibb Company; 2015 Apr 25 [accessed 2015 May 06]. [4 p]. … New York (NY): The New York Times Company; 2015 Apr 30 [accessed 2015 May 27]. [7 p]. … Available: http://www.cepheid.com/company/news- events/press-releases/? … releaseID=787563 http://www.cepheid.com/company/news-events/press-releases/?

19. Infectious Disease Including HIV/AIDS #09 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1412.pdf
    December 22, 2014 - Princeton (NJ): Bristol-Myers Squibb Company; 2014 Apr 07 [accessed 2014 May 15]. [3 p]. … Princeton (NJ): Bristol-Myers Squibb Company; 2014 Mar 24 [accessed 2014 May 15]. [4 p]. … New York (NY): The New York Times Company; 2014 Dec 22 [accessed 2014 Dec 23]. [8 p]. … Available: http://www.cepheid.com/company/news- events/press-releases/? … releaseID=787563 http://www.cepheid.com/company/news-events/press-releases/?

20. Disposition of Comments for CER 175 Total Worker Health (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/worker-health_disposition-comments.pdf
    May 31, 2016 - There is a broad area of focus on various integrated company management strategies and how these might … are not aware of any prior review that supports the effectiveness of integration on other areas of company … Why would integration matter, versus two Independent but highly effective HP and OSH programs at a company … Does integration add unnecessary complexity that hurts the simple cost/benefit analysis of a company … TEP Reviewer #1 General Company onsite clinics were traditionally occ health nurses doing work comp